Skip to main content

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Publication ,  Journal Article
Walsh, TJ; Pappas, P; Winston, DJ; Lazarus, HM; Petersen, F; Raffalli, J; Yanovich, S; Stiff, P; Greenberg, R; Donowitz, G; Schuster, M ...
Published in: N Engl J Med
January 24, 2002

BACKGROUND: Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. METHODS: In a randomized, international, multicenter trial, we compared voriconazole, a new second-generation triazole, with liposomal amphotericin B for empirical antifungal therapy. RESULTS: A total of 837 patients (415 assigned to voriconazole and 422 to liposomal amphotericin B) were evaluated for success of treatment. The overall success rates were 26.0 percent with voriconazole and 30.6 percent with liposomal amphotericin B (95 percent confidence interval for the difference, -10.6 to 1.6 percentage points); these rates were independent of the administration of antifungal prophylaxis or the use of colony-stimulating factors. There were fewer documented breakthrough fungal infections in patients treated with voriconazole than in those treated with liposomal amphotericin B (8 [1.9 percent] vs. 21 [5.0 percent], P=0.02). The voriconazole group had fewer cases of severe infusion-related reactions (P<0.01) and of nephrotoxicity (P<0.001). The incidence of hepatotoxicity was similar in the two groups. Patients receiving voriconazole had more episodes of transient visual changes than those receiving liposomal amphotericin B (22 percent vs. 1 percent, P<0.001) and more hallucinations (4.3 percent vs. 0.5 percent, P<0.001). Parenteral voriconazole was changed to the oral formulation in 22 percent of the voriconazole group, with a reduction in the mean duration of hospitalization by one day in all patients (P=0.17) but by two days in patients at high risk (P=0.03). CONCLUSIONS: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 24, 2002

Volume

346

Issue

4

Start / End Page

225 / 234

Location

United States

Related Subject Headings

  • Voriconazole
  • Triazoles
  • Pyrimidines
  • Prospective Studies
  • Neutropenia
  • Neoplasms
  • Mycoses
  • Middle Aged
  • Male
  • Infusions, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., … National Institute of Allergy and Infectious Diseases Mycoses Study Group. (2002). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 346(4), 225–234. https://doi.org/10.1056/NEJM200201243460403
Walsh, Thomas J., Peter Pappas, Drew J. Winston, Hillard M. Lazarus, Finn Petersen, John Raffalli, Saul Yanovich, et al. “Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.N Engl J Med 346, no. 4 (January 24, 2002): 225–34. https://doi.org/10.1056/NEJM200201243460403.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225–34.
Walsh, Thomas J., et al. “Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.N Engl J Med, vol. 346, no. 4, Jan. 2002, pp. 225–34. Pubmed, doi:10.1056/NEJM200201243460403.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J, National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225–234.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 24, 2002

Volume

346

Issue

4

Start / End Page

225 / 234

Location

United States

Related Subject Headings

  • Voriconazole
  • Triazoles
  • Pyrimidines
  • Prospective Studies
  • Neutropenia
  • Neoplasms
  • Mycoses
  • Middle Aged
  • Male
  • Infusions, Intravenous